---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-014136"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:41:43.772028+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Foghorn Therapeutics reduces ATM program capacity from $200M to $100M

## Summary
- Amendment No. 1 to Sales Agreement with TD Cowen lowers maximum shares to be sold from $200M to $100M.
- Other terms of the at-the-market offering program remain unchanged; no new public offering announced.
- Amendment effective March 20, 2025; shares sold pursuant to previously effective shelf registration.

## SEC filing metadata
- accession: 0001628280-25-014136
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828025014136/0001628280-25-014136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828025014136/fhtx-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-014136
- JSON: https://secwatch.observer/filing/0001628280-25-014136.json
- Plain text: https://secwatch.observer/filing/0001628280-25-014136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.